940 related articles for article (PubMed ID: 35590083)
21. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
22. Electrical impedance myography detects dystrophin-related muscle changes in mdx mice.
Hiyoshi T; Zhao F; Baba R; Hirakawa T; Kuboki R; Suzuki K; Tomimatsu Y; O'Donnell P; Han S; Zach N; Nakashima M
Skelet Muscle; 2023 Nov; 13(1):19. PubMed ID: 37980539
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.
Li J; Wang K; Zhang Y; Qi T; Yuan J; Zhang L; Qiu H; Wang J; Yang HT; Dai Y; Song Y; Chang X
Circulation; 2021 Nov; 144(22):1760-1776. PubMed ID: 34698513
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration.
Siemionow M; Biegański G; Niezgoda A; Wachowiak J; Czarnota J; Siemionow K; Ziemiecka A; Sikorska MH; Bożyk K; Heydemann A
Stem Cell Rev Rep; 2023 Nov; 19(8):2724-2740. PubMed ID: 37707670
[TBL] [Abstract][Full Text] [Related]
25. P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
Sinadinos A; Young CN; Al-Khalidi R; Teti A; Kalinski P; Mohamad S; Floriot L; Henry T; Tozzi G; Jiang T; Wurtz O; Lefebvre A; Shugay M; Tong J; Vaudry D; Arkle S; doRego JC; Górecki DC
PLoS Med; 2015 Oct; 12(10):e1001888. PubMed ID: 26461208
[TBL] [Abstract][Full Text] [Related]
26. Long-term effect of human mini-dystrophin in transgenic mdx mice improves muscle physiological function.
Chu X; Li J; Qiao C; Wang J; Wang Y; Jiang XC; You H; Xiao X; Wang B
FASEB J; 2021 Jun; 35(6):e21628. PubMed ID: 33982338
[TBL] [Abstract][Full Text] [Related]
27. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy.
Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887
[TBL] [Abstract][Full Text] [Related]
28. Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy.
Mucha O; Podkalicka P; Kaziród K; Samborowska E; Dulak J; Łoboda A
Skelet Muscle; 2021 Sep; 11(1):21. PubMed ID: 34479633
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
[TBL] [Abstract][Full Text] [Related]
30. Accumulation of Dystrophin-Positive Muscle Fibers and Improvement of Neuromuscular Junctions in mdx Mouse Muscles after Bone Marrow Transplantation under Different Conditions.
Sokolova AV; Domnina AP; Mikhailov VM
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240237
[TBL] [Abstract][Full Text] [Related]
31. Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10.
Nitahara-Kasahara Y; Hayashita-Kinoh H; Chiyo T; Nishiyama A; Okada H; Takeda S; Okada T
Hum Mol Genet; 2014 Aug; 23(15):3990-4000. PubMed ID: 24659498
[TBL] [Abstract][Full Text] [Related]
32. Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.
Niezgoda A; Biegański G; Wachowiak J; Czarnota J; Siemionow K; Heydemann A; Ziemiecka A; Sikorska MH; Bożyk K; Siemionow M
Arch Immunol Ther Exp (Warsz); 2023 Nov; 71(1):24. PubMed ID: 37999748
[TBL] [Abstract][Full Text] [Related]
33. Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy.
Chun JL; O'Brien R; Song MH; Wondrasch BF; Berry SE
Stem Cells Transl Med; 2013 Jan; 2(1):68-80. PubMed ID: 23283493
[TBL] [Abstract][Full Text] [Related]
34. Why is early-onset atrial fibrillation uncommon in patients with Duchenne muscular dystrophy? Insights from the mdx mouse.
Nguyen MN; Hooper C; Stefanini M; Vrellaku B; Carnicer R; Wood MJ; Simon JN; Casadei B
Cardiovasc Res; 2024 Apr; 120(5):519-530. PubMed ID: 38270932
[TBL] [Abstract][Full Text] [Related]
35. Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.
Blain AM; Greally E; McClorey G; Manzano R; Betts CA; Godfrey C; O'Donovan L; Coursindel T; Gait MJ; Wood MJ; MacGowan GA; Straub VW
PLoS One; 2018; 13(6):e0198897. PubMed ID: 29912990
[TBL] [Abstract][Full Text] [Related]
36. Autologous Cell Therapy Approach for Duchenne Muscular Dystrophy using PiggyBac Transposons and Mesoangioblasts.
Iyer PS; Mavoungou LO; Ronzoni F; Zemla J; Schmid-Siegert E; Antonini S; Neff LA; Dorchies OM; Jaconi M; Lekka M; Messina G; Mermod N
Mol Ther; 2018 Apr; 26(4):1093-1108. PubMed ID: 29503200
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy.
Albini S; Palmieri L; Dubois A; Bourg N; Lostal W; Richard I
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511179
[TBL] [Abstract][Full Text] [Related]
38. Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy.
Wasala NB; Bostick B; Yue Y; Duan D
Hum Mol Genet; 2013 Jul; 22(13):2634-41. PubMed ID: 23459935
[TBL] [Abstract][Full Text] [Related]
39. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.
Gutpell KM; Hrinivich WT; Hoffman LM
PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927
[TBL] [Abstract][Full Text] [Related]
40. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
